Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).[7][8]
The most common side effects are low levels of neutrophils (a type of white blood cell), diarrhea, nausea, anemia (low red blood cell counts), nose and throat infection and tiredness.[8]
Venetoclax attaches to a protein called Bcl-2.[8] This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines.[8] By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease.[8]
^"Venetoclax (Venclexta) Use During Pregnancy". Drugs.com. 29 May 2019. Retrieved 25 April 2020.
^"AusPAR: Venetoclax". Therapeutic Goods Administration (TGA). 26 April 2022. Retrieved 27 April 2022.
^"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
^"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
^"Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
^"Venclyxto 10 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 21 April 2020. Retrieved 25 April 2020.
^ abcCite error: The named reference Venclexta FDA label was invoked but never defined (see the help page).
^ abcdefCite error: The named reference Venclyxto EPAR was invoked but never defined (see the help page).
Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic...
juvenile myelomonocytic leukemia. The combination of azacitidine and venetoclax is also approved for AML. Azacitidine is a chemical analogue of the nucleoside...
the aim of not harming normal cells. Targeted drugs used in CLL include venetoclax (a Bcl-2 inhibitor), ibrutinib and acalabrutinib (Bruton's tyrosine kinase...
to be one of the most up-regulated (i.e. overactive) genes in BPDCN. Venetoclax inhibits the apoptosis-inhibiting action of BCL-2 and proved active in...
Penicillamine Trimethoprim/sulfamethoxazole Clozapine Valproate Vaccination Venetoclax Severe bacterial infections, especially in people with underlying hematological...
about 15-20% of multiple myeloma patients) may particularly benefit from Venetoclax therapy (which is FDA approved for other blood cancers but not yet available...
(paclitaxel, docetaxel, gemcitabine, and irinotecan), olaparib, erlotinib, venetoclax, and rituximab in advanced hematological malignancies (in both pediatric...
tofacitinib ALK inhibitors, e.g. crizotinib Bcl-2 inhibitors (e.g. FDA approved venetoclax, obatoclax in clinical trials, navitoclax, and gossypol. PARP inhibitors...
(alectinib): Treatment for non-small cell lung cancer (NSCLC). 2016: Venclexta (venetoclax): Treatment for patients with chronic lymphocytic leukemia (CLL) who have...
the compound was assigned the international nonproprietary name (INN) venetoclax. Similarly, other compounds may be given a USAN or BAN for example. Finally...
Global Information
